However, although TIA1 silencing in these cells may impair SG formation (absence of G3BP1 positive SG when TIA1 is silenced in some cells) (Figure 1G), it only slightly impairs sorafenib resistance of hepatic cancer cells (Figure 1H). This evidence concerns the gene G3BP1 and liver cancer.